SciClone to Hold Symposium on New Therapies in Liver Cancer and Hepatitis C Virus
Posted on: Wednesday, 16 April 2008, 06:00 CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will hold a symposium titled "New Therapies in Liver Cancer and Hepatitis" during the 43rd annual meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy. SciClone and Sigma-Tau will host the meeting on April 24, 2008, from 11:00 a.m. to 12:00 p.m. local time in Hall Yellow 1 in the Milan Convention Center.
Experts in the field of liver disease will discuss ZADAXIN(R), generically referred to as thymalfasin or thymosin alpha 1, and its therapeutic benefits as a treatment for the hepatitis C virus (HCV) and liver cancer.
-- Enrico Garaci, M.D., Professor of Microbiology at the University of Rome "Tor Vergata" in Rome, Italy will present the immunomodulatory activities of thymalfasin against infectious agents. -- Alessia Ciancio, M.D., Professor in the Department of Gastroenterology at the University of Torino in Torino, Italy will discuss the treatment of hepatitis C non-responders with pegylated interferon, ribavirin and thymalfasin. -- Robert Gish, M.D., Medical Director of the Liver Disease Management and Transplantation Program at the California Pacific Medical Center in San Francisco will detail treatment of hepatocellular carcinoma (liver cancer) with TACE plus thymalfasin.
About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of hepatitis C and malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese pharmaceutical market by in-licensing or acquiring the marketing rights to other products, such as DC Bead(TM). For the U.S. market, SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.
Corporate Contact: Erin Murphy SciClone Pharmaceuticals, Inc. (650) 358-3437 Email Contact
SOURCE: SciClone Pharmaceuticals, Inc.
Source: MARKET WIRE
Related Articles
- Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
- SciClone's Phase III Hepatitis Trial Fails Endpoint
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Amrubicin is Designated As an Orphan Medicinal Product By the European Commission for the Treatment of Small Cell Lung Cancer
- Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
- FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
- What Price for Health and Drugs? Treatment Could Raise Cost of Cancer Fight
- Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C
- Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
 |
 |
User Comments (0)
RSS Feeds